Omeros Corporation (OMER)
NASDAQ · Manufacturing · Pharmaceutical preparations
OMER price, last 12 months
Key stats
- Previous close
- $14.55
- Open
- $14.65
- Day range
- $13.80 – $14.71
- 52-week range
- $6.70 – $21.24
- Volume
- 1.3M
- Avg volume (20 days)
- 1.3M
- Market cap
- $1.3B
Performance
Technicals and fundamentals
About Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $1.3B